Axonics (Nasdaq:AXNX) today announced it acquired lead placement technology from Radian to speed up the placement of implantable leads for sacral neuromodulation.
Axonics acquired the assets of Radian from Intermed Labs for an undisclosed amount. The company expects the product to receive FDA clearance and be available on a commercial basis in mid-2024.
The acquired technology has the potential to reduce procedure times and enable more accurate placement of temporary leads during peripheral nerve evaluation. Using a standard X-ray image of a patient’s pelvis, a physician can use the software to determine the optimal location for needle entry and lead placement based on patient anatomy. It can be implemented into existing clinical workflows as it takes only minutes to use and requires minimal training.
In long-term sacral neuromodulation (SNM) therapy, physicians determine patient eligibility by conducting a peripheral nerve evaluation or external trial. However, locating the proper sacral foramen can be challenging during the PNE trial, particularly without real-time imaging such as fluoroscopy. The acquired technology offers a solution, consisting of a software application and a hardware tool, to simplify, speed up and enhance the accuracy of PNE lead placement. With this solution, physicians’ confidence in the procedure is expected to increase.
“Since Axonics’ founding, our SNM development efforts have focused on enhancing the physician and patient experience,” Axonics CEO Raymond Cohen said in a news release. “We expect the Radian technology will improve patient comfort, increase physician confidence and SNM access, simplify the learning curve for physicians new to SNM, and increase PNE trial success rates, which should ultimately result in more adults being treated with our life-changing SNM therapy. We are confident that empowering physicians with innovative technology and tools has the potential to drive significant SNM market expansion in the years ahead.”
